Clinical Trial Data Management In The Post-COVID Era

Accelerated by COVID-19 restrictions, the shift to decentralized or hybrid clinical trials is expanding the scope of drug development at multiple levels. It has implications for demographic reach and diversity, patient experiences and convenience, cost efficient, and the range and granularity of clinical measurements and data available in real time from remote devices.

Decentralization has also brought a wealth of new technologies and methodologies into the clinical trial arena. Despite their undoubted advantages, though, these innovations can mean increased workload and complexity for trial managers. One challenge is ensuring that disparate technologies provide as seamless and integrated an experiences as possible, enhancing speed and efficiency while optimizing the value of patient-generated data.